Proactive Investors
22 Jun 2026, 17:38 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Definium Therapeutics' Phase 3 Emerge study for DT120 in treating major depressive disorder met its primary endpoint and all key secondary efficacy endpoints. — Meeting Phase 3 endpoints is the critical final hurdle for FDA approval and commercialization of a new drug, significantly increasing the company's valuation.
+0.90DT120 demonstrated a statistically significant (p<0.0001) 8.1-point placebo-adjusted improvement in MADRS scores at Week 6. — High statistical significance and a clear efficacy margin provide strong evidence for the drug's clinical viability compared to placebos.
+0.70DT120 was reported as generally well tolerated, with 99% of adverse events being mild to moderate and no serious adverse events or suicidality signals identified. — A clean safety profile is essential for regulatory approval, especially for psychiatric medications involving controlled substances.
+0.60Continue reading
6 related stories
Search tags
Definium Therapeutics (NASDAQ:DFTX) shares increased by approximately 53% following the release of these results. — This reflects the immediate market digestion of the news, though it is a lagging indicator of the clinical results themselves.
+0.30Which stocks this story touches
Shares rose 53% following positive Phase 3 trial results for its major depressive disorder treatment.
Mentioned in the context of a CEO interview regarding exploration strategy without specific positive or negative news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
9h ago
